Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer

Article Oncology

Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.

Shun Lu et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study.

Shun Lu et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

Gilberto de Castro Jr et al.

Summary: In the NEPTUNE study, first-line durvalumab plus tremelimumab did not show significant improvement in overall survival compared to chemotherapy in patients with metastatic NSCLC.

JOURNAL OF THORACIC ONCOLOGY (2023)

添加到收藏夹

News Item Dermatology

Neoadjuvant pembrolizumab improves eventfree survival in melanoma

T. Schwarz

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

Mariano Provencio et al.

Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Sapna P. Patel et al.

Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Review Oncology

Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent

Bruna Pellini et al.

Summary: Circulating tumor DNA minimal residual disease is a powerful biomarker with the potential to improve survival outcomes for non-small-cell lung cancer. Although the current studies are limited in size, largely retrospective, and without thorough prospective clinical validation, the detection of ctDNA minimal residual disease has shown good sensitivity and specificity at the first post-treatment timepoint, and improved performance in surveillance.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer

Jamie E. Chaft et al.

Summary: Biomarker-informed clinical trials are pushing the treatment of early-stage lung cancer beyond cytotoxic chemotherapy, with the incorporation of targeted and immunotherapies. Adjuvant osimertinib, preoperative chemoimmunotherapy, and adjuvant immunotherapy could improve outcomes for resectable lung cancer patients, and ongoing or planned studies focusing on biomarkers, immunotherapy, and targeted therapy may further enhance survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

David R. Spigel et al.

Summary: The study examined the efficacy of consolidation durvalumab in patients with non-small-cell lung cancer, showing significant improvements in overall survival and progression-free survival, with manageable safety. The 5-year follow-up data continued to demonstrate the positive effects of durvalumab on survival and disease progression.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer

Betty C. Tong et al.

Summary: This study demonstrates that neoadjuvant pembrolizumab is safe and well tolerated in patients with non-small cell lung cancer, and it is not associated with increased surgical morbidity or mortality. Minimally invasive approaches may be more challenging in cases with neoadjuvant immunotherapy. Pathologic response is higher compared to standard neoadjuvant chemotherapy.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2022)

添加到收藏夹

Article Oncology

Deciphering radiological stable disease to immune checkpoint inhibitors

J. Luo et al.

Summary: Stable disease (SD) defined in immunotherapy is common and diverse, mainly reflecting tumor growth rate rather than response to immune checkpoint inhibitors. When the progression-free survival (PFS) of stable disease patients with no tumor growth exceeds 6 months, they can be considered as "SD responders". This definition improves the efficiency and insight of clinical and translational research.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

SHR-1316 vs placebo in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: A randomized, double-blind, multicenter, phase Ib/III trial

Y-L. Wu et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC

Fan Zhang et al.

Summary: This study reports the long-term clinical outcomes of patients with NSCLC receiving PD-1 inhibitors as neoadjuvant therapy. The results show that patients with positive PD-L1 expression and high tumor mutation burden have favorable clinical outcomes.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

D. Koenig et al.

Summary: In operable stage III non-small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel +/- neoadjuvant sequential radiotherapy has shown favorable long-term outcomes. Complete resection and pathological complete remission are important predictors of prognosis.

ESMO OPEN (2022)

添加到收藏夹

Article Oncology

Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.

Judith M. Versluis et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.

Fuming Qiu et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.

Samuel Rosner et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio et al.

Summary: Neoadjuvant chemotherapy plus nivolumab demonstrates effectiveness in resectable non-small cell lung cancer. Pretreatment ctDNA levels significantly correlate with survival outcomes and outperform radiologic assessments in predicting survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

Biagio Ricciuti et al.

Summary: This study reveals the association between different tumor mutation burden (TMB) levels and immunotherapy efficacy in non-small cell lung cancer (NSCLC) patients. The findings show that increasing TMB levels are associated with immune cell infiltration and an inflammatory T-cell-mediated response.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article

Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease

Elizabeth A. Mittendorf et al.

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2022)

添加到收藏夹

Meeting Abstract Oncology

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial

I. Bahce et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816

J. S. Deutsch et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC

H. Wakelee et al.

Journal of Thoracic Oncology (2022)

添加到收藏夹

Article Oncology

PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

M. Provencio et al.

Journal of Thoracic Oncology (2022)

添加到收藏夹

Article Oncology

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O'Brien et al.

Summary: This study evaluated the use of Pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC. The results showed that Pembrolizumab significantly improved disease-free survival in both the overall population and the PD-L1 TPS of 50% or greater population.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Jamie E. Chaft et al.

Summary: This study examined the use of neoadjuvant atezolizumab in patients with resectable non-small cell lung cancer. It found that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab, but further studies are needed to confirm these findings.

NATURE MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Solange Peters et al.

Summary: Selection of non-small cell lung cancer patients based on high blood-based tumor mutation burden did not improve clinical response, further research is needed.

NATURE MEDICINE (2022)

添加到收藏夹

Article Oncology

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Diana Merino Vega et al.

Summary: This study evaluated the role of circulating tumor DNA (ctDNA) in monitoring the response to immune checkpoint inhibitors (ICI) in patients with non-small-cell lung cancer. Pooled analysis of clinical trial data from five independent studies showed consistent and strong associations between reductions in ctDNA levels and improved overall survival (OS) and progression-free survival (PFS). CtDNA may serve as an important tool for early indication of treatment benefit.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience

Florian Eichhorn et al.

Summary: The study investigated the therapeutic effect and safety of neoadjuvant PD-1 inhibitor pembrolizumab in non-small cell lung cancer patients, showing it to be feasible and tolerable with manageable toxicity. Major pathological response was associated with PD-L1 expression >=10% and significant tumor target response in PET-CT.

LUNG CANCER (2021)

添加到收藏夹

Correction Multidisciplinary Sciences

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers (vol 596, pg 126, 2021)

Justina X. Caushi et al.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone et al.

Summary: The NEOSTAR trial showed that neoadjuvant treatment with nivolumab + ipilimumab combination therapy can improve pathologic response rates in operable NSCLC patients and has better clinical efficacy compared to nivolumab alone.

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study

Hongtao Duan et al.

Summary: The study showed that neoadjuvant therapy with a combination of chemotherapy and PD-1 inhibitors is safe and effective in patients with resectable NSCLC, resulting in a high overall response rate (ORR), major pathological response (MPR), and pathological complete response (pCR).

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

添加到收藏夹

Meeting Abstract Oncology

MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD plus after curative-intent therapy

D. R. Spigel et al.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

94TiP Neoadjuvant tislelizumab or placebo + platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non-small cell lung cancer (NSCLC): A phase III trial in progress

C. Wang et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Oncology

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

J. Lee et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Meeting Abstract Oncology

Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial

M. Wislez et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Editorial Material Oncology

Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot

Yelena Y. Janjigian et al.

Summary: Immune checkpoint blockade (ICB) has revolutionized cancer treatment, starting with metastatic melanoma patients and now extending to various types of cancer at different stages. Research is ongoing to understand the history and mechanisms behind the response variations, as well as the integration of ICB into different treatment approaches.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

Marta Casarrubios et al.

Summary: The study aimed to characterize the T-cell receptor (TCR) repertoire as a potential predictive biomarker for pathologic response to immunotherapy in locally advanced nonsmall cell lung cancer (NSCLC). The analysis revealed a positive association between an uneven TCR repertoire in tissue samples and complete pathologic response (CPR) after surgery. Furthermore, top 1% TCR clones in diagnostic biopsies showed potential as predictive biomarkers for CPR, outperforming PD-L1 tumor proportion score (TPS) and tumor mutational burden (TMB).

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Meeting Abstract Oncology

Phase II trial of toripalimab plus chemotherapy as neoadjuvant treatment in resectable stage III non-small cell lung cancer (NeoTPD01 Study).

Zerui Zhao et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

添加到收藏夹

Article Oncology

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer

Jiajia Zhang et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Oncology

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

William D. Travis et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Shugeng Gao et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Review Multidisciplinary Sciences

Neoadjuvant checkpoint blockade for cancer immunotherapy

Suzanne L. Topalian et al.

SCIENCE (2020)

添加到收藏夹

Article Oncology

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Shirish Gadgeel et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.

Tina Cascone et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Catherine A. Shu et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Learning from clinical trials of neoadjuvant checkpoint blockade

Judith M. Versluis et al.

NATURE MEDICINE (2020)

添加到收藏夹

Meeting Abstract Oncology

Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial

B. Besse et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Luis Paz-Ares et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

Joshua E. Reuss et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Meeting Abstract Oncology

A randomised, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in locally advanced NSCLC

J. Lei et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab

Suzanne L. Topalian et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Meeting Abstract Oncology

Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

M. Garassino et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

Valsamo Anagnostou et al.

CANCER RESEARCH (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer

Matthew J. Bott et al.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2019)

添加到收藏夹

Article Oncology

Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers

Rajat K. Das et al.

CANCER DISCOVERY (2019)

添加到收藏夹

Article Oncology

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

Jing Liu et al.

ONCOIMMUNOLOGY (2019)

添加到收藏夹

Review Oncology

Tertiary lymphoid structures in the era of cancer immunotherapy

Catherine Sautes-Fridman et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Article Oncology

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

T. R. Cottrell et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

P. M. Forde et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity

Ludmila Danilova et al.

CANCER IMMUNOLOGY RESEARCH (2018)

添加到收藏夹

Article Oncology

FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma

A. C. Tan et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Meeting Abstract Oncology

Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer

Tina Cascone et al.

CANCER RESEARCH (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Oncology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Spencer C. Wei et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Christian U. Blank et al.

NATURE MEDICINE (2018)

添加到收藏夹

Meeting Abstract Oncology

IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab plus Chemotherapy

N. Rizvi et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer

Kari Chansky et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Immunology

Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

Helene Salmon et al.

IMMUNITY (2016)

添加到收藏夹

Article Oncology

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

Jing Liu et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non-Small Cell Lung Cancer

Feiran Lou et al.

ANNALS OF THORACIC SURGERY (2014)

添加到收藏夹

Review Medicine, General & Internal

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

Sarah Burdett et al.

LANCET (2014)

添加到收藏夹

Article Oncology

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non-Small-Cell Lung Cancer Combined Analysis of Two IFCT Randomized Trials

Guillaume Mouillet et al.

JOURNAL OF THORACIC ONCOLOGY (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

SAMHD1 restricts HIV-1 infection in resting CD4+ T cells

Hanna-Mari Baldauf et al.

NATURE MEDICINE (2012)

添加到收藏夹

Article Oncology

Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group

Jean-Pierre Pignon et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer

相关参考文献

导出引文

分享论文